Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-05-25

Clinical Trial Update: Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing two shortening regimens that include moxifloxacin for pulmonary tuberculosis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Moxifloxacin (moxifloxacin)

Snippet

Sponsor: Global Alliance for TB Drug Development | Conditions: Pulmonary Tuberculosis | Phase 3 | Status: COMPLETED | Results posted: 2015-05-25